These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

985 related items for PubMed ID: 16735841

  • 1. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
    Seeman E.
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
    [Abstract] [Full Text] [Related]

  • 2. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
    Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ.
    Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
    [Abstract] [Full Text] [Related]

  • 3. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S.
    Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [Abstract] [Full Text] [Related]

  • 4. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
    Ortolani S, Vai S.
    Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
    [Abstract] [Full Text] [Related]

  • 5. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY.
    J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
    [Abstract] [Full Text] [Related]

  • 6. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older.
    Seeman E, Vellas B, Benhamou C, Aquino JP, Semler J, Kaufman JM, Hoszowski K, Varela AR, Fiore C, Brixen K, Reginster JY, Boonen S.
    J Bone Miner Res; 2006 Jul; 21(7):1113-20. PubMed ID: 16813532
    [Abstract] [Full Text] [Related]

  • 7. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
    Seeman E, Boonen S, Borgström F, Vellas B, Aquino JP, Semler J, Benhamou CL, Kaufman JM, Reginster JY.
    Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
    [Abstract] [Full Text] [Related]

  • 8. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
    Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ.
    J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
    [Abstract] [Full Text] [Related]

  • 9. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
    Cortet B.
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
    [Abstract] [Full Text] [Related]

  • 10. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S.
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
    Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP.
    Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
    [Abstract] [Full Text] [Related]

  • 12. A new treatment for post-menopausal osteoporosis: strontium ranelate.
    Rizzoli R.
    J Endocrinol Invest; 2005 Dec; 28(8 Suppl):50-7. PubMed ID: 16323829
    [Abstract] [Full Text] [Related]

  • 13. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
    Boonen S.
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
    [Abstract] [Full Text] [Related]

  • 14. Strontium ranelate in the prevention of osteoporotic fractures.
    Reginster JY, Malaise O, Neuprez A, Bruyere O.
    Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
    [Abstract] [Full Text] [Related]

  • 15. [Strontium ranelate: a new therapeutic principle for postmenopausal osteoporosis].
    Mosekilde L, Nielsen LR, Vestergaard P.
    Ugeskr Laeger; 2005 Sep 12; 167(37):3485-7. PubMed ID: 16159455
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA, Foo AC, Lai MM, Glendenning P.
    Bone; 2009 May 12; 44(5):744-51. PubMed ID: 19130909
    [Abstract] [Full Text] [Related]

  • 17. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
    Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY.
    Adv Ther; 2008 Dec 12; 25(12):1235-56. PubMed ID: 19066755
    [Abstract] [Full Text] [Related]

  • 18. [The efficacy of strontium ranelate (Osseor) on fractures in osteoporosis].
    Novak S.
    Reumatizam; 2008 Dec 12; 55(2):75-7. PubMed ID: 19024282
    [Abstract] [Full Text] [Related]

  • 19. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.
    Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ.
    J Clin Endocrinol Metab; 2005 May 12; 90(5):2816-22. PubMed ID: 15728210
    [Abstract] [Full Text] [Related]

  • 20. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
    Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.
    N Engl J Med; 2004 Jan 29; 350(5):459-68. PubMed ID: 14749454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.